norastemizole on Fc epsilon RI
receptor-mediated signal transduction processes.
Eur. J. Pharmacol., 322(1), 97-105 (1997).
7. Woestenborghs, R., et al., Simultaneous
determination of astemizole
Saksela, E. et al., Immunological Rev., 71-123 (1979).
Krishnaraj, R. Cell. Immunol., 141, 306-322 (1992).
Neutrophils
Arnould, T. et al., Blood, 83, 3705-3716 (1994).
Read, R.A. et
3. Field, L. et al., J. Chem. Soc. Perkin Trans. I, 249,
(1978).
4. Samouilov, A. and Zweier, J.L., Anal. Biochem.
258, 322, (1998).
5. Kowaluk, E.A. et al., Eur. J. Pharmacol. 144, 379,
(1987
Saksela, E. et al., Immunological Rev., 71-
123 (1979).
Krishnaraj, R. Cell. Immunol., 141, 306-322
(1992).
Neutrophils
Arnould, T. et al., Blood, 83, 3705-3716
(1994).
Read, R.A. et al
No. 528114 5 mg €91
Ref.: Ferrandi, C ., et al . 2007 . J. Pharmacol. Exp. Ther. 322, 923 .
PI 3-Kg/CKII Inhibitor
(5-(4-Fluoro-2-hydroxyphenyl)furan-2-ylmethylene)thiazolidine-2,4-dione
A cell-permeable
L and 5 L
Height, diameter and net weight (bottle size):
206 mm, ø 101 mm, approx. 66 g (1 L)
322 mm, ø 125 mm, approx. 145 g (2.5 L)
330 mm, ø 178 mm, approx. 335 g (5 L)
H3 (pSer10) H0412 3020 H3F3A P NP_002098.1 y y y
321 HDAC-1 H3284 3065 HDAC1 P NP_004955.2 y y n/d
322 HDAC-1 H6287 3065 HDAC1 M NP_004955.2 y y n/d
323 HDAC-2 H3159 3066 HDAC2 P NP_001518.3 y y n/d
324
H3 (pSer10) H0412 3020 H3F3A P NP_002098.1 y y y
321 HDAC-1 H3284 3065 HDAC1 P NP_004955.2 y y n/d
322 HDAC-1 H6287 3065 HDAC1 M NP_004955.2 y y n/d
323 HDAC-2 H3159 3066 HDAC2 P NP_001518.3 y y n/d
324